2,763 results match your criteria Journal of Viral Hepatitis [Journal]


Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.

J Viral Hepat 2019 Apr 13. Epub 2019 Apr 13.

The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

People who are homeless have increased hepatitis C virus (HCV) infection risk, and are less likely to access primary healthcare. We aimed to evaluate HCV RNA prevalence, liver disease burden, linkage to care and treatment uptake and outcomes among people attending a homelessness service in Sydney. Participants were enrolled in an observational cohort study with recruitment at a homelessness service over eight liver health campaign days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13112DOI Listing
April 2019
1 Read

Treatment and Monitoring of Children with Chronic Hepatitis C in the Pre-DAA Era: a European Survey of 38 Paediatric Specialists.

J Viral Hepat 2019 Apr 13. Epub 2019 Apr 13.

University College London Institute of Child Health.

The burden of paediatric HCV infection across Europe is unknown, as are current policies regarding monitoring and treatment. This collaborative study aimed to collect aggregate data to characterise the population of ≤18-year olds with HCV infection in specialist follow up in a twelve-month period (2016) across the PENTAHep European consortium, and investigate current policies around monitoring and treatment. A cross-sectional, web-based survey was distributed in April 2017 to 50 paediatricians in 19 European countries, covering patients' profile, and monitoring and treatment practices. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13111
Publisher Site
http://dx.doi.org/10.1111/jvh.13111DOI Listing
April 2019
3 Reads

Management of HCV in Children in the Era of DAA's.

J Viral Hepat 2019 Apr 13. Epub 2019 Apr 13.

Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Chronic hepatitis C certainly is a global health burden in children as well as in adults. Spontaneous viral clearance can occur in early childhood but is uncommon thereafter. Although the majority of cases are asymptomatic during childhood and young adulthood, without an effective treatment, children who acquire HCV via vertical transmission can develop chronic liver disease and other complications including end stage liver disease and hepatocellular carcinoma in adulthood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13113DOI Listing
April 2019
2 Reads

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.

J Viral Hepat 2019 Apr 13. Epub 2019 Apr 13.

Department of Medicine, University of Florida, Gainesville, Florida, United States.

Patients infected with hepatitis C virus (HCV) treated with interferon-free direct-acting antivirals may still require ribavirin. However, ribavirin is associated with adverse events that can limit its use. This open-label, multicenter, Phase 3 study evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir+dasabuvir (OBV/PTV/r+DSV) with low-dose ribavirin for 12 weeks in genotype 1a-infected patients without cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13109DOI Listing

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis.

J Viral Hepat 2019 Apr 12. Epub 2019 Apr 12.

University of Liverpool, Liverpool, United Kingdom.

Although direct acting antivirals (DAA) for chronic Hepatitis C virus (HCV) infection are highly efficacious and safe, treatment initiation is often limited in patients with neuropsychiatric disorders due to concerns over reduced treatment adherence and drug-drug interactions. Here, we report adherence, efficacy, safety, and patient-reported outcomes (PROs) from an integrated analysis of registrational studies using the pangenotypic DAA regimen of glecaprevir and pibrentasvir (G/P). Patients with chronic HCV genotypes 1-6 infection with compensated liver disease (with or without cirrhosis) receiving G/P for 8, 12, or 16 weeks were included in this analysis. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13110
Publisher Site
http://dx.doi.org/10.1111/jvh.13110DOI Listing
April 2019
2 Reads

Age, race and viral genotype are associated with the prevalence of Hepatitis B e antigen in children and adults with chronic Hepatitis B.

J Viral Hepat 2019 Apr 11. Epub 2019 Apr 11.

University of California at San Francisco.

Hepatitis B e antigen (HBeAg) is an important serological marker of hepatitis B virus (HBV) infection and is associated with higher levels of viremia, increased risk of infectivity to others and increased risk of hepatocellular carcinoma. We analyzed HBeAg status in a large cohort of adults and children enrolled in Cohort Studies of the Hepatitis B Research Network, long-term natural history studies of chronic HBV infection. A cross sectional analysis examined factors associated with HBeAg positivity, including demographic and virologic data, across the age spectrum. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13104
Publisher Site
http://dx.doi.org/10.1111/jvh.13104DOI Listing
April 2019
3 Reads

A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical-practice: evidence of a relevant risk of death and evolution from silent to chronic infection.

J Viral Hepat 2019 Apr 11. Epub 2019 Apr 11.

Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy.

The study was undertaken in order to provide a snapshot from real-clinical practice of virological presentation and outcome of patients developing immunosuppression-driven HBV-reactivation. 70 patients with HBV-reactivation were included (66.2% treated with rituximab, 10% with corticosteroids, and 23. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13101DOI Listing

Serum keratin-18 fragments as cell death biomarker in association with disease progression and prognosis in HBV-related cirrhosis.

J Viral Hepat 2019 Apr 11. Epub 2019 Apr 11.

Department of Infectious Diseases, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Extensive hepatocyte death leads to hepatic inflammation and contributes to systemic inflammation in decompensated cirrhosis. We aimed to investigate the prognostic value of serum cell death markers in patients with Hepatitis B virus (HBV)-related acute decompensation (AD) of cirrhosis with and without acute-on-chronic liver failure (ACLF). We studied two cohorts - cohort 1: 201 outpatients with stable chronic hepatitis B (49 cirrhosis); cohort 2: 232 inpatients with HBV-related cirrhosis admitted for AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13100DOI Listing
April 2019
3 Reads

Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals.

J Viral Hepat 2019 Apr 11. Epub 2019 Apr 11.

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.

Prediction of hepatocellular carcinoma (HCC) development after sustained virological response (SVR) is clinically important and the usefulness of noninvasive markers for prediction HCC have been reported. The aim of this study was to compare the prediction accuracy for HCC development by noninvasive markers. A total of 346 patients with chronic hepatitis C without history of HCC who achieved SVR through direct acting antivirals were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13103DOI Listing
April 2019
1 Read

Expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus (HCV) infection and in subjects who spontaneously cleared the virus.

J Viral Hepat 2019 Apr 10. Epub 2019 Apr 10.

Department of Immunopathology of Infectious and Parasitic Diseases, Medical University of Warsaw, Warsaw, Poland.

Chronic hepatitis C virus (HCV) infection is characterized by increased proportion of CD4+CD8+ double positive (DP) T cells, but their role in this infection is unclear. In chronic hepatitis C, immune responses to HCV become functionally exhausted, which manifests itself by increased expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on T cells. The aim of our study was to determine PD-1 and Tim-3 phenotype of DP T cells in subjects with naturally resolved and chronic HCV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13108DOI Listing
April 2019
1 Read

Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.

J Viral Hepat 2019 Apr 10. Epub 2019 Apr 10.

Roche Products Ltd, Welwyn Garden City, UK.

In a multicenter, genome-wide association study to identify host genetic factors associated with treatment response in adult chronic hepatitis B patients, genotype data were obtained by microarray analysis from 1669 patients who received peginterferon alfa-2a for ≥24 weeks with/without a nucleos(t)ide analog. Treatment response was assessed at least 24 weeks post-treatment, using serological and/or virological endpoints. Thirty-six single-marker analyses and a gene-by-gene analysis were conducted. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13107
Publisher Site
http://dx.doi.org/10.1111/jvh.13107DOI Listing
April 2019
4 Reads

Maternal HBsAg carriers and adverse pregnancy outcomes: a hospital-based prospective cohort analysis.

J Viral Hepat 2019 Apr 10. Epub 2019 Apr 10.

Department of Epidemiology, Key Laboratory for Public Health Safety, School of Public Health; Fudan University, Shanghai, 200032, China.

It is not clear whether chronic hepatitis B virus (HBV) infection during pregnancy can increase the risk of adverse pregnancy outcomes for both mothers and neonates. We conducted a hospital-based prospective cohort study on pregnant women (PW) and used an analysis strategy that was guided by directed acyclic graphs (DAGs). Maternal characteristics and major adverse pregnancy outcomes were collected both from questionnaires and hospital-based electronic medical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13105DOI Listing
April 2019
1 Read

HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.

J Viral Hepat 2019 Apr 10. Epub 2019 Apr 10.

Translational Medicine Institute, Hospital of Chenzhou, University of South China, Chenzhou, Hunan, 423000, China.

Hepatitis C virus (HCV) and hepatitis B virus (HBV) coinfection reciprocally influences viral replication and host defense responses. This study aimed to investigate the impact of HBV coinfection on circulating T follicular helper cell (cTfh) distribution and the HCV neutralizing antibody (nAb) response. HCV neutralizing antibody responses were measured in individuals with HCV monoinfection (n=83) and HBV/HCV coinfection (n=78) using the HCV pseudoparticle neutralization assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13106DOI Listing
April 2019
1 Read
3.909 Impact Factor

Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus are equivalent between genotype B and C in long term.

J Viral Hepat 2019 Mar 28. Epub 2019 Mar 28.

Department of Gastroenterology, Yamagata University, Faculty of Medicine, Yamagata, Yamagata, 990-9585, Japan.

Hepatitis B virus (HBV) genotypes B (HBV/B) and C (HBV/C) are the most prevalent genotypes among Japanese patients with hepatitis. Reportedly, HBV/C infection has been associated with more severe disease progression, manifesting as developing cirrhosis and hepatocellular carcinoma (HCC), than HBV/B infection. However, no long-term studies have examined the development of HCC in HBV/B-infected patients in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13099DOI Listing
March 2019
2 Reads

Electronic Health Record Year and Country of Birth Testing and Patient Navigation to Increase Diagnosis of Chronic Viral Hepatitis.

J Viral Hepat 2019 Mar 28. Epub 2019 Mar 28.

Laboratory Services, St. Joseph's Medical Center, Paterson, New Jersey.

The United States Preventive Services Task Force recommends hepatitis C testing people born from 1945-1965, "Birth cohort" as well as hepatitis C and hepatitis B testing people from countries of birth with endemic infection risk. We automated the hospital electronic health record system to test birth cohort and those born in countries with endemic infection risk. A script is launched searching the laboratory database upon registration for any hepatitis C-antibody, Hepatitis C-RNA, and/or Hepatitis B-surface antigen result. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13098DOI Listing
March 2019
4 Reads

Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.

J Viral Hepat 2019 Mar 21. Epub 2019 Mar 21.

Department of Viroscience, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Hepatitis B e antigen (HBeAg) seroconversion experienced during nucleo(s)tide analogue (NUC) therapy is often not sustained. We aimed to study whether hepatitis B core-related antigen (HBcrAg) levels predict sustained HBeAg seroconversion in patients treated with NUCs. We studied HBeAg-positive patients treated with NUCs for at least 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13097DOI Listing
March 2019
1 Read

Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study.

J Viral Hepat 2019 Mar 21. Epub 2019 Mar 21.

Immunisation, Hepatitis, and Blood Safety Department, National Infection Service, Public Health England, London, UK.

Through record linkage we describe causes of death among persons with diagnosis of HCV in England. Persons ≥1yrs with anti-HCV/HCV-PCR tests reported to PHE sentinel surveillance during 2002-2016 were linked to death registrations from the Office for National Statistics during 2008-2016. We fouind that 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13096DOI Listing
March 2019
1 Read

Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval.

J Viral Hepat 2019 Mar 21. Epub 2019 Mar 21.

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

The degree of liver fibrosis in chronic hepatitis B (CHB) infection influences outcome and management. Existing data describing the long-term dynamic changes of liver fibrosis are limited. This study aimed to evaluate the evolution of liver fibrosis in CHB across a 10-year period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13095DOI Listing
March 2019
2 Reads

Hepatitis C seroprevalence and engagement in related care and treatment among trans women.

J Viral Hepat 2019 Feb 27. Epub 2019 Feb 27.

Department of Epidemiology, School of Public Health, Rutgers University, Piscataway, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13089DOI Listing
February 2019

Biological basis for functional cure of chronic hepatitis B.

J Viral Hepat 2019 Feb 25. Epub 2019 Feb 25.

Cancer Research Center of Lyon (CRCL), Lyon, France.

Chronic hepatitis B (CHB) infection affects over 250 millon people worldwide and 800000 are expected to die yearly due to the development of hepatocellular carcinoma (HCC). Current antiviral therapies include nucleoside analogs (NAs) that target the viral retrotranscriptase inhibiting de novo viral production. Pegylated interferon (Peg-IFN) is also effective in reducing the viral DNA load in serum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13090DOI Listing
February 2019
1 Read

Advanced liver disease in Russian children and adolescents with chronic hepatitis C.

J Viral Hepat 2019 Feb 25. Epub 2019 Feb 25.

University College London Institute of Child Health, University College London, London, UK.

Russia has one of the highest prevalences of paediatric chronic hepatitis C infection (CHC). Our aim was to provide a detailed characterization of children and adolescents with CHC including treatment outcomes. Thus, an observational study of children with CHC aged <18 years was conducted in three hepatology centres from November 2014 to May 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13093DOI Listing
February 2019
1 Read

Can we stop nucleoside analogues before HBsAg loss?

J Viral Hepat 2019 Feb 25. Epub 2019 Feb 25.

Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Athens, Greece.

Most of the current guidelines and the existing data suggest that long-term therapy with nucleos(t)ide analogue(s) [NA(s)] may be stopped in carefully selected chronic hepatitis B patients who remain HBsAg positive. In particular, NA(s) may be discontinued in such patients without pre-existing cirrhosis who achieved long-term on-therapy virological remission (>12 months of HBeAg seroconversion and HBV DNA undetectability for initially HBeAg-positive cases; ≥3 years of HBV DNA undetectability for HBeAg-negative cases) and are expected to remain under close follow-up after NA(s) discontinuation. The majority of patients will develop post-NA(s) virological relapses and a proportion of them will have biochemical relapses and occasionally flares, but prompt retreatment can reintroduce remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13091DOI Listing
February 2019

HCV reinfection as a positive indication of high-risk population treatment access.

Authors:
Gregory J Dore

J Viral Hepat 2019 Feb 25. Epub 2019 Feb 25.

Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13092DOI Listing
February 2019

Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis.

J Viral Hepat 2019 Feb 23. Epub 2019 Feb 23.

Singapore Clinical Research Institute, Singapore, Singapore.

Therapeutic vaccines may be promising treatments for chronic hepatitis B (CHB), but their clinical efficacy and safety are unclear. We conducted a systematic review of the evidence for the efficacy and safety of therapeutic vaccines in CHB patients. We searched PubMed, EMBASE and Google Scholar from 1990 until present and abstracts from EASL, APASL and AASLD from 2012 to 2017 and selected randomized controlled trials of CHB patients, comparing therapeutic vaccines with no treatment or standard of care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13085DOI Listing
February 2019
1 Read

Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.

J Viral Hepat 2019 Feb 23. Epub 2019 Feb 23.

Burnet Institute, Melbourne, VIC, Australia.

A barrier to hepatitis C treatment for people who inject drugs (PWID) is needing to attend multiple appointments for diagnosis. Point-of-care hepatitis C tests provide results within 20 to 105 minutes and can be offered opportunistically in nonclinical settings such as needle syringe programmes. In this nested qualitative study, we explored the acceptability of point-of-care testing for PWID. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13087DOI Listing
February 2019
1 Read

Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct-acting antiviral regimens.

J Viral Hepat 2019 Feb 23. Epub 2019 Feb 23.

University of Vermont Medical Center, Burlington, Vermont.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13083DOI Listing
February 2019

Genetic diversity of hepatitis D virus genotype-1 in Europe allows classification into subtypes.

J Viral Hepat 2019 Feb 23. Epub 2019 Feb 23.

Institute of Virology, Technische Universität München, Munich, Germany.

Hepatitis delta virus (HDV) is an RNA virus which leads to both acute and chronic forms of hepatitis. At present, HDV isolates have been classified into eight major genotypes distributed over different geographical regions. Recent increase in HDV sequences in Europe and worldwide has enabled us to revisit the taxonomic classification of HDV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13086DOI Listing
February 2019
1 Read

The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period.

J Viral Hepat 2019 Feb 22. Epub 2019 Feb 22.

Infectious Diseases Unit, IRCCS "San Matteo", University of Pavia, Pavia, Italy.

Hepatitis A is a self-limiting infection representing the most common cause of viral hepatitis worldwide. Despite being a low incidence region, in the European Union, an increasing number of cases have been reported since summer 2016, resulting in a large outbreak in 2017, involving mainly men who have sex with men (MSM). Some reports described a different clinical course of hepatitis A virus in patients infected by human immunodeficiency virus (HIV) or MSM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13082DOI Listing
February 2019
3 Reads

New treatment options for delta virus: Is a cure in sight?

Authors:
Cihan Yurdaydin

J Viral Hepat 2019 Feb 16. Epub 2019 Feb 16.

Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.

Current treatment of chronic hepatitis D viral infection with interferons is poorly tolerated and effective only in a minority of patients. Despite delta virus causing the most severe form of chronic viral hepatitis, no other treatments are available. After many years of inactivity, there is now hope for new treatment approaches for delta virus and some are likely to enter clinical practice in the near future. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13081
Publisher Site
http://dx.doi.org/10.1111/jvh.13081DOI Listing
February 2019
7 Reads

Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.

J Viral Hepat 2019 Feb 11. Epub 2019 Feb 11.

Department of Gastroenterology, Ege University School of Medicine, İzmir, Turkey.

The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13075DOI Listing
February 2019
2 Reads

Chronic hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Laboratorio de Biología Molecular, División Patología, Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP- CONICET-GCBA), Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

In Chronic hepatitis B (CHB) infection, virus and immune response interplay is thought to be responsible for pathogenesis. Yet, the impact of each immune cell population and viral protein expression in liver damage is still unknown. Our aim was to study the interplay between intrahepatic immune response and viral activity in relation to CHB liver damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13078DOI Listing
February 2019
5 Reads

Vitamin D deficiency and health-related quality of life in chronic hepatitis C.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Hepatology Unit, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13076DOI Listing
February 2019
2 Reads
3.909 Impact Factor

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.

J Viral Hepat 2019 Feb 10. Epub 2019 Feb 10.

Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.

Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4. To evaluate whether these results translate to clinical practice, data were pooled from observational studies across 13 countries. Treatment-naïve or -experienced patients, with or without cirrhosis, received OBV/PTV/r ± DSV ± RBV according to approved local labels and clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13080DOI Listing
February 2019
2 Reads

Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Merck & Co., Inc., Kenilworth, New Jersey.

In clinical trials, the three-drug regimen of ruzasvir (RZR) 60 mg, uprifosbuvir (UPR) 450 mg and grazoprevir 100 mg, with or without ribavirin, has demonstrated promising efficacy and excellent tolerability across a wide range of hepatitis C virus (HCV)-infected individuals. The present study assessed the efficacy and safety of the two-drug combination of RZR 60 mg plus UPR 450 mg administered for 12 weeks in participants with HCV genotype (GT) 1-6 infection. In this open-label clinical trial, treatment-naive or -experienced and cirrhotic or noncirrhotic participants with chronic HCV GT1-6 infection received RZR 60 mg plus UPR 450 mg orally once daily for 12 weeks (NCT02759315/protocol PN035). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13079
Publisher Site
http://dx.doi.org/10.1111/jvh.13079DOI Listing
February 2019
12 Reads

Age-stratified anti-HAV positivity in Pune, India after two decades: Has voluntary vaccination impacted overall exposure to HAV?

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Department of Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Pune, India.

The degree of transmission of hepatitis A virus (HAV) is inversely proportional to the socioeconomic status of a community. Serosurveys conducted at Pune, India during 1982-98 documented significant reduction in HAV exposure of paediatric, higher socioeconomic status (HSS) population. Anti-HAV positivity (ELISA) in age-stratified Pune population representing HSS and lower middle socioeconomic status (LMSS) (n = 1065) and infants till the age of 15 months (n = 690) was determined in 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13074DOI Listing
February 2019
3 Reads

Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population-based cohort study.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.

Diabetes mellitus may be a risk factor of HCC development in chronic hepatitis B infected patients and affect the all-cause mortality. This study aimed to examine whether DM was associated with the development of HCC with CHB and affected the all-cause mortality. A total of 2966 CHB patients newly diagnosed with DM in 2000 were retrieved from the Longitudinal Cohort of Diabetes Patients database and used propensity scores matching based on age, sex-gender, alcohol-related liver disease and baseline liver cirrhosis to compare with the non-DM patients from the Taiwanese National Health Insurance Research Database. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13077
Publisher Site
http://dx.doi.org/10.1111/jvh.13077DOI Listing
February 2019
10 Reads

High prevalence and poor linkage to care of transfusion-transmitted infections among blood donors in Dar-es-Salaam, Tanzania.

J Viral Hepat 2019 Feb 3. Epub 2019 Feb 3.

Department of Hepatology, Imperial College London, St Mary's Hospital, London, UK.

Blood transfusion is one of the most commonly relied upon therapies in sub-Saharan Africa. Existing safeguards recommended include systematic screening for transfusion-transmitted infections and restricted voluntary nonremunerated blood donor selection. We report the transfusion-transmitted infection screening and notification practice at a large urban blood transfusion centre in Dar-es-Salaam, Tanzania. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13073DOI Listing
February 2019
4 Reads
3.909 Impact Factor

MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of haem oxygenase-1 expression.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

MicroRNAs are small noncoding RNAs that are central factors between hepatitis C virus (HCV) and host cellular factors for viral replication and liver disease progression, including liver fibrosis, cirrhosis and hepatocellular carcinoma. In the present study, we found that overexpressing miR-let-7c markedly reduced HCV replication because it induced haem oxygenase-1 (HO-1) expression by targeting HO-1 transcriptional repressor Bach1, ultimately leading to stimulating an antiviral interferon response and blockade of HCV viral protease activity. In contrast, the antiviral actions of miR-let-7c were attenuated by miR-let-7c inhibitor treatment, exogenously expressing Bach1 or suppressing HO-1 activity and expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13072DOI Listing
January 2019
1 Read

HBV T1719G mutation reduced HBV replication through mutant Enh II and HBx protein in vitro.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R. China.

It was repeatedly reported that the hepatitis B virus (HBV) T1719G mutation was very common and related to progression and malignancy of liver disease. However, its effect on viral replication efficiency remains unclear. In this study, we aimed to evaluate the function and mechanisms of the T1719G mutation on viral replication capacity. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13070
Publisher Site
http://dx.doi.org/10.1111/jvh.13070DOI Listing
January 2019
8 Reads

Interferon-free therapy as the cause of white matter tracts and cerebral perfusion recovery in patients with chronic hepatitis C.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Department of General Radiology, Interventional Radiology and Neuroradiology, Wroclaw Medical University, Wroclaw, Poland.

The purpose of this study was to assess cerebral microstructural and perfusion changes in patients with chronic hepatitis C virus (HCV) infection before and after interferon-free therapy, using advanced magnetic resonance (MR) techniques. Eleven HCV-positive patients underwent diffusion tensor imaging (DTI) and perfusion-weighted imaging (PWI) using a 1.5T MR unit, before and 24 weeks after completion of interferon-free therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13069DOI Listing
January 2019
2 Reads

Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Department of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

The optimal duration of treatment with nucleos(t)ide analogues (NAs) for patients with HBeAg-negative chronic hepatitis B (CHB) is unknown. The aim of this study was to identify an immune signature associated with off-treatment remission to NA therapy. We performed microarray analysis of peripheral blood mononuclear cell (PBMCs) from six patients with chronic hepatitis B who stopped NA therapy (three with off-treatment remission, three with relapse) and five patients with chronic HBV infection (previously termed 'inactive carriers') served as controls. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13068
Publisher Site
http://dx.doi.org/10.1111/jvh.13068DOI Listing
January 2019
12 Reads

Testing for hepatitis C virus infection in UK prisons: What actually happens?

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK.

Prisons are a key demographic in the drive to eradicate hepatitis C virus (HCV) as a major public health threat. We have assessed the impact of the recently introduced national opt-out policy on the current status of HCV testing in 14 prisons in the East Midlands (UK). We analysed testing rates pre- and post-introduction of opt-out testing, together with face-to-face interviews with prison healthcare and management staff in each prison. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13071DOI Listing
January 2019

Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.

J Viral Hepat 2019 Jan 21. Epub 2019 Jan 21.

Statistics Modelling and Economics Department, National Infection Service, Public Health England, London, UK.

In England, 160 000 individuals were estimated to be chronically infected with hepatitis C virus (HCV) in 2005 and the burden of severe HCV-related liver disease has increased steadily for the past 15 years. Direct-acting antiviral treatments can clear infection in most patients, motivating HCV elimination targets. However, the current burden of HCV is unknown and new methods are required to monitor progress. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13063
Publisher Site
http://dx.doi.org/10.1111/jvh.13063DOI Listing
January 2019
11 Reads

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.

J Viral Hepat 2019 Jan 21. Epub 2019 Jan 21.

University of Alberta, Edmonton, AB, Canada.

This study evaluated 12-week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir- and velpatasvir-containing regimen. All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13067
Publisher Site
http://dx.doi.org/10.1111/jvh.13067DOI Listing
January 2019
8 Reads

Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.

J Viral Hepat 2019 Jan 20. Epub 2019 Jan 20.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Hepatocellular carcinoma (HCC) incidence is high in The Gambia, and hepatitis B virus (HBV) infection is the main cause. People coinfected with HBV and hepatitis D virus (HDV) have an even greater risk of HCC and cirrhosis. Using a new HDV quantitative microarray antibody capture (Q-MAC) assay, we evaluated the association between HDV infection and HCC or cirrhosis among participants in The Gambia Liver Cancer Study. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13065
Publisher Site
http://dx.doi.org/10.1111/jvh.13065DOI Listing
January 2019
13 Reads
3.909 Impact Factor

Hepatitis E virus in Spanish donors and the necessity for screening.

J Viral Hepat 2019 Jan 19. Epub 2019 Jan 19.

Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba, Cordoba, Spain.

Hepatitis E virus (HEV) represents a major health problem worldwide. As the course of HEV cases is often subclinical, asymptomatic infections could represent an important source of viral spread and infection via routes such as blood donations. Before universal screening for HEV in blood donations can be implemented, studies evaluating the incidence of infection are needed to establish the potential risk of viral transmission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13064DOI Listing
January 2019
7 Reads

Clinical features and determinants of chronicity in hepatitis E virus infection.

J Viral Hepat 2019 Apr 5;26(4):414-421. Epub 2019 Feb 5.

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, Maryland.

Hepatitis E virus (HEV) has traditionally been associated with an acute, self-limiting hepatitis and is not known to have any chronic sequelae. HEV genotypes 1 and 2, which are human pathogens, have been associated with this self-limiting presentation, in both sporadic and epidemic settings. HEV genotype 3, which is zoonotically transmitted, is increasingly being reported as a cause of chronic infection in immunocompromised patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13059
Publisher Site
http://dx.doi.org/10.1111/jvh.13059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437685PMC
April 2019
6 Reads